Evotec is a German drug-discovery and development partner that provides integrated R&D services and collaborative pipelines to pharmaceutical and biotech clients. Work spans early discovery, preclinical development, and shared-risk alliances that can include co-owned assets. The model blends fee-for-service capacity with longer-term partnerships rather than a classic fully integrated pharma sales franchise.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 200 | — | -31.6 | — |
| Q2 2025 | 171.2 | — | -43.5 | — |
| Q3 2025 | 163.9 | — | -43.1 | — |
| Q4 2025 | 253.3 | — | 14.6 | — |
| Q1 2026 | 156.6 | -21.7% | -121.9 | — |
All markets — KeepWinning global stock screener
Other companies on MDAX: Stabilus (STM), HelloFresh (HFG), Talanx (TLX), Hochtief (HOT), Traton (8TRA), Knorr-Bremse (KBX)